Cargando…
Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing
Antisense oligonucleotide (ASO)-based therapy is one of the next-generation therapy, especially targeting neurological disorders. Many cases of ASO-dependent gene expression suppression have been reported. Recently, we developed a tocopherol conjugated DNA/RNA heteroduplex oligonucleotide (Toc-HDO)...
Autores principales: | Asada, Ken, Sakaue, Fumika, Nagata, Tetsuya, Zhang, Ji-chun, Yoshida-Tanaka, Kie, Abe, Aya, Nawa, Makiko, Nishina, Kazutaka, Yokota, Takanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136785/ https://www.ncbi.nlm.nih.gov/pubmed/33928345 http://dx.doi.org/10.1093/nar/gkab258 |
Ejemplares similares
-
Highly efficient silencing of microRNA by heteroduplex oligonucleotides
por: Yoshioka, Kotaro, et al.
Publicado: (2019) -
Separation-related rapid nuclear transport of DNA/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking
por: Ono, Daisuke, et al.
Publicado: (2020) -
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing
por: Nishina, Kazutaka, et al.
Publicado: (2015) -
DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo
por: Ohyagi, Masaki, et al.
Publicado: (2021) -
Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo
por: Kuwahara, Hiroya, et al.
Publicado: (2018)